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Abstract
Infections by opportunistic bacteria have significant contributions to morbidity and mortality of hospitalized patients and
also lead to high expenses in healthcare. In this setting, one of the major clinical problems is caused by Gram-positive
bacteria such as enterococci and staphylococci. In this study we extract, purify, identify and characterize immunogenic
surface-exposed proteins present in the vancomycin resistant enterococci (VRE) strain Enterococcus faecium E155 using
three different extraction methods: trypsin shaving, biotinylation and elution at high pH. Proteomic profiling was carried out
by gel-free and gel-nanoLC-MS/MS analyses. The total proteins found with each method were 390 by the trypsin shaving,
329 by the elution at high pH, and 45 using biotinylation. An exclusively extracytoplasmic localization was predicted in 39
(10%) by trypsin shaving, in 47 (15%) by elution at high pH, and 27 (63%) by biotinylation. Comparison between the three
extraction methods by Venn diagram and subcellular localization predictors (CELLO v.2.5 and Gpos-mPLoc) allowed us to
identify six proteins that are most likely surface-exposed: the SCP-like extracellular protein, a low affinity penicillin-binding
protein 5 (PBP5), a basic membrane lipoprotein, a peptidoglycan-binding protein LysM (LysM), a D-alanyl-D-alanine
carboxypeptidase (DdcP) and the peptidyl-prolyl cis-trans isomerase (PpiC). Due to their close relationship with the
peptidoglycan, we chose PBP5, LysM, DdcP and PpiC to test their potential as vaccine candidates. These putative surface-
exposed proteins were overexpressed in Escherichia coli and purified. Rabbit polyclonal antibodies raised against the
purified proteins were able to induce specific opsonic antibodies that mediated killing of the homologous strain E. faecium
E155 as well as clinical strains E. faecium E1162, Enterococcus faecalis 12030, type 2 and type 5. Passive immunization with
rabbit antibodies raised against these proteins reduced significantly the colony counts of E. faecium E155 in mice, indicating
the effectiveness of these surface-related proteins as promising vaccine candidates to target different enterococcal
pathogens.
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Introduction
Enterococci have emerged as important nosocomial pathogens
due to their multiple antibiotic resistances [1]. E. faecalis and E.
faecium are the third and fourth most commonly isolated
nosocomial pathogens worldwide, causing up to 14% and 9,6%
of hospital acquired infections in the US and Europe, respectively
[2–4]. Especially E. faecium infections have become a major
concern, since resistance to vancomycin and ampicillin have
increased to almost 100% in some institutions in the US, and a
similar rise of resistances has been observed recently also in
Europe [5–7]. The ability of this species to survive under a range
of adverse environmental conditions, and its dramatic increase in
antibiotic resistance worldwide highlights the need for the
development of alternative treatment and prevention strategies
[8,9]. To date, many different surface antigens have been
identified in E. faecalis and E. faecium, but only a few of these
may be promising vaccine candidates [10].
In Gram-positive bacteria, the cell wall is composed of a
peptidoglycan macromolecule that protects bacteria against
environmental conditions and serves as anchor for the attachment
of capsular polysaccharides, teichoic acids, and proteins that are
covalently or non-covalently attached to peptidoglycan [11].
Surface proteins have an important role in the interactions
between the bacterial cell and its environment. They are involved
in adhesion and invasion of the host cell, sensing the physico-
chemical conditions of the environment and sending signals to the
cytoplasm, in mounting defenses against the host responses and
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toxicity [12–15]. Therefore, surface proteins have become
attractive targets for drug development [16–18]. Their ability to
interact with the host immune system makes them interesting
vaccine candidates, since protein based vaccines may overcome
some of the challenges encountered by polysaccharide-based
vaccines, like serotype-dependent coverage, high production costs,
and low immunogenicity [19,20]. Despite these advantages, only
few surface and secreted proteins have been studied in clinically
relevant enterococci. Aggregation substance (AS) protein and the
collagen adhesin Ace have been examined in E. faecalis [21,22]
and enterococcal surface protein Esp, secreted antigen protein
SagA and two ABC transporters have been tested for antigenicity
in E. faecium [23–25]. Using appropriate in vitro and in vivo
models to confirm protective efficacy, only SagA, Ace and an ABC
transporter were identified as potential vaccine candidates [10,23].
There are several strategies for the identification of surface
proteins. The most widely used techniques are in silico analysis of
the genome (‘‘reverse vaccinology’’), bacterial cell wall fraction
analysis by Two-dimensional gel electrophoresis (2-DE) coupled to
mass spectrometry, partial enzymatic digestion of cell wall proteins
by trypsin (trypsin shaving) and biotinylation [26,27]. New
bioinformatic approaches have been developed and these strate-
gies have significantly improved the prediction of bacterial protein
localization. These include the pipelines SLEP (Surface Localiza-
tion Extracellular Proteins), developed by Giombini et al [28],
LocateP developed by Zhou et al [29], and SurfG+ developed by
Barinov et al [30]. However, these in silico approaches are still not
fully reliable and do not provide detailed surface protein
localization in the bacterial cell wall [26]. Separations of the
membrane and cell wall fractions are analyzed by 2-DE, gel
excision of the protein spots and analysis by mass- spectrometry
(MS). This strategy has been used in other Gram-positive bacteria
[31,32] and is fairly well established. However, the preparations
are usually contaminated with cytoplasmic proteins and often give
insufficient information regarding surface exposure, similar to the
in silico approach [26]. Recently, trypsin shaving has been used in
E. faecalis, group A Streptococci, Bacillus subtilis and Staphylo-
coccus aureus [26,27,33,34]. This strategy is based on the
proteolytic digestion of surface-exposed proteins from intact cells
and the analysis of the resulting peptides by liquid chromatogra-
phy/tandem-mass-spectrometry (LC-MS/MS). The principal ad-
vantage of this technique is that it allows a rapid and more
selective identification of the surface-exposed proteins. However, it
leads to the identification of many cytoplasmic proteins and
further verification of location of the identified proteins is
necessary [26,27,34]. Using biotinylation, intact cells are treated
with Sulfo-NHS-SS-Biotin, to which the cell membrane is
impermeable. It reacts specifically with the e-amino-group of
lysine residues of surface-exposed proteins. Subsequently, labeled
proteins can be separated by affinity chromatography with
streptavidin from whole-cell lysates and these can be analyzed
by LC-MS/MS or 2-DE [27,32]. Despite the advantages of being
relatively simple to use and facilitating the identification of more
predicted surface-exposed proteins compared to cytoplasmic
proteins, this method has the major disadvantage that biotin has
poor affinity to sortase-attached surface proteins leading to low
detection for these important protein antigens [27].
In the current study, we compared the above-described gel-free
methods, i.e. trypsin shaving and biotinylation, to correlate the
results between them and identify surface protein candidates with
greater accuracy. We describe the subsequent overexpression,
purification and immunological characterization of surface protein
candidates present in hospital-associated vancomycin-resistant E.
faecium E155 [35] to evaluate their potential role as targets for
immunotherapy.
Materials and Methods
Bacterial strains and sera
The bacterial strains and sera used for the present study are
listed in the Table 1. For the production of polyclonal antibodies
against the recombinant proteins, New Zealand white rabbits were
immunized with two subcutaneous injections of 10 mg protein
given 2 weeks apart; in the third week, three injections of 5 mg
were given intravenously. Finally, in the fifth week two injections
of 5 mg were given intravenously and the terminal bleeding was
collected in the seventh week. Serum from terminal bleedings was
heat inactivated at 56uC for 30 min and frozen at 220uC before
being used in experiments.
Protein extraction by trypsin shaving
Extractions were performed as described by Tjalsma et al. [34].
Briefly, two aliquots of 50 mL of bacterial cultures of E. faecium
E155 grown in brain heart infusion (BHI) were harvested at an
OD600 nm = 0.4 by centrifugation (10.000 r.p.m., 2 min) and
washed twice with 4 mL Bicam (triethylammonium bicarbonate
buffer 100 mM pH 8.0). Then the cells were resuspended in
600 mL of Bicam. The first aliquot was mixed with trypsin
(Promega) at a final concentration of 10 mg/mL in Bicam. The
second aliquot was resuspended in Bicam without any trypsin. All
the samples were incubated for 1 h at 37uC with gentle shaking.
After centrifugation (7500 r.p.m., 5 min), the cell pellets were
removed and the supernatants were treated with 1 mM dithio-
threitol (DTT) for 30 min, followed by 1 mM iodoacetamide
(IAA), also for 30 min at room temperature. Finally, fresh trypsin
(0.5 mg) was added to all samples and tryptic cleavage was
continued for 18 h at 37uC. Proteins identified from the extraction
of the second aliquot were digested with trypsin overnight and
considered as ‘controls’ to be subtracted from the proteins
identified in the cells treated with trypsin after mass spectrometry
identification.
Protein extraction by biotinylation
Surface-exposed proteins were labeled and extracted by
exposure of cells to Sulfo-NHS-SS-Biotin using a protocol
described by Hempel et al. [36] with the following modifications:
100 mL of bacterial cultures of E. faecium E155 grown in BHI at
OD600 nm = 0.5 harvested at 80006 g for 5 min at 4uC. About
0.2 g of wet cell pellet was resuspended in 5 mL ice-cold
phosphate buffered saline (PBS pH 8.0) with 1 mM phenylmethyl-
sulfonyl fluoride (PMSF) and mixed with 0.6 mg of sulfo-NHS-SS-
Biotin (Thermo Scientific) previously dissolved in 100 mL of PBS.
The mixture was incubated by gentle shaking for 1 h on ice.
Unbound biotinylation reagent was removed by centrifugation at
80006 g for 1 min at 4uC and washed three times with ice cold
PBS (pH 8.0)/500 mM glycine. Disruption of cells was performed
mechanically in a FastPrep cell disrupter (Zymo Research) at 6 m/
s2 twice for 30 s. The cell debris was recovered from the glass
beads with a total of 3 mL of PBS (pH 8.0). The lysate was
centrifuged (100.0006 g for 1 h at 4uC), the cell debris
resuspended in a total of 400 mL of PBS (pH 8.0), supplemented
with 5% IAA and homogenized in the cell disrupter at 6 m/s2
twice for 30 s with 0.25 mL of glass beads. The proteins were then
solubilized by addition of 100 mL of PBS (pH 8.0) with 1 mM
PMSF, 4% CHAPS (3-[(3-cholamidopropyl)dimethylammonio]-1-
propanesulfonate) and 2% ASB-14 (amidosulfobetaine-14). A
second homogenization step was done after detergent addition
Vaccine Candidates against Enterococci
PLOS ONE | www.plosone.org 2 November 2014 | Volume 9 | Issue 11 | e111880
under the same conditions as mentioned above. Cell debris was
removed by centrifugation (14000 r.p.m., 15 min) after 1 h of
incubation with the detergent. The biotinylated proteins were
isolated and purified by NeutrAvidin (Thermo Scientific) agarose
affinity-purification. For a reaction volume of 500 mL protein
mixture 150 mL of NeutrAvidin agarose resin was washed twice
with PBS (pH 8.0)/1% NP-40 and centrifuged at 1000 r.p.m. for
1 min at 4uC. The resin was mixed with the cell lysate for 1 h by
gently shaking on ice. The supernatant was removed and the resin-
bound complex washed. Biotinylated proteins were eluted twice by
incubation with 1 mL of elution buffer (5% mercaptoethanol in
H2O) for 1 h with gentle shaking. Supernatant was then recovered
after centrifugation at 1000 r.p.m. for 1 min and mixed with 8 mL
of cold acetone (220uC, overnight). The precipitated proteins
were harvested by centrifugation (8500 r.p.m., 30 min, 4uC) and
washed twice with 1 mL of cold 98% ethanol (4uC). Finally the
pellets were dried in a Concentrator 5301 (Eppendorf) for 2 min
and dissolved in 15 mL 6M urea/2M thiourea for 2 min at 80uC.
Elution of cell-wall-associated proteins at high pH
Surface-exposed proteins were extracted by exposure of cells to
high pH using a protocol described by Morsczeck et al. [37]. A cell
pellet from a 50 mL culture of E. faecium E155 grown in BHI to
OD600 = 0.5 was washed with a PBS sucrose solution (100 mM
NaCl, 60 mM sucrose, 55 mM sodium phosphate, pH 7.2), and
then gently shaken for 1 h at room temperature in 2 mL NaOH
glycine sucrose (glycine 50 mM, sucrose 60 mM, pH 12.4). After
centrifugation (30 min, 10.0006g), 108 mL 1 M HCl and 100 mL
1 M Tris-HCl (pH 7.0) were added to 1 mL supernatant. Proteins
were precipitated at 4uC by addition of 8 mL cold acetone
overnight. The protein pellet obtained after centrifugation
(10 min, 10.0006 g) was resuspended in 200 mL of Tris-HCl
(pH 7.5). After an aliquot of 25 mL of the protein solution was run
through SDS-PAGE and Coomassie blue staining, each gel line
with the protein-containing region was cut in five pieces. After
each piece was digested with trypsin as is described in the mass-
spectrometry section.
Mass-spectrometry analyses
Overnight tryptic digestion of the obtained proteins (or peptides)
was performed after each extraction method, and subsequently,
MS analyses were performed as described elsewhere [38]. In brief,
the samples extracted by trypsin shaving, biotinylation and
alkaline extraction were treated with 0.5 mg trypsin (Promega)
overnight at 37uC. Trypsin-cleaved samples were desalted and
concentrated to obtain 1–2 mg of peptides on a tipmicroC18 Omix
(Agilent) before nano-liquid chromatography nanoLC-MS/MS
analysis. The chromatography step was performed on a nano-LC
system (Prominence, Shimadzu). Peptides were concentrated on a
Zorbax 560.3 mm C18 precolumn (Agilent) and separated onto a
Zorbax 150675 mm C18 column (Agilent). Mobile phases
consisted of 0.1% trifluoroacetic acid, 99.9% water (v/v) (A) and
0.1% trifluoroacetic acid, 20% water in 79.9% ACN (v/v/v) (B).
The nanoflow rate was set at 300 nL/min, and the gradient profile
was as follows: constant 7% B for 5 min, from 7 to 70% B in
183 min, from 70 to 100% B in 5 min, and return to 7% B. The
300 nL/min volume of the peptide solution was mixed with
1.2 mL/min volumes of solutions of 5 mg/mL CHCA matrix
prepared in a diluent solution of 50% ACN with 0.1% TFA.
Twenty nine second fractions were spotted by an AccuSpot spotter
(Shimadzu) on a stainless steel Opti-TOF 384 targets. MS
experiments were performed on an AB SCIEX 5800 proteomics
analyzer equipped with TOF ion optics and OptiBeam on-axis
laser irradiation with a 1000 Hz repetition rate. The resulting
fragmentation patterns were used to determine the sequences of
the peptides. Database searching was performed using the mascot
Table 1. Bacterial strains and sera used for this study.
Strain or serum Description* Reference or source
Strains
E. faecium E155 ARE, VRE strain isolated from a patient in the USA
(Chicago), CC17
[35]
E. faecium E1162 ARE strain isolated from blood in the Netherlands, CC17 [72]
E. faecalis 12030 isolated from a patient in the USA (Cleveland) [44]
E. faecalis type 2 isolated from a patient in Japan (Sapporo) [73]
E. faecalis type 5 isolated from a patient in Japan (Kobe) [73]
E coli M15pRep4 M15 harboring pREP4 plasmid (INVITROGEN)
E. coli M15/pQE30LysM M15 harboring pREP4 and pQE30LysM plasmids This study
E. coli M15/pQE30PpiC M15 harboring pREP4 and pQE30PpiC plasmids This study
E. coli M15/pQE30DdcP M15 harboring pREP4 and pQE30DdcP plasmids This study
E. coli M15/pQE30PBP5 M15 harboring pREP4 and pQE30PBP5 plasmids This study
Sera
NRS Preimmune sera from rabbit This study
aSagA Rabbit serum raised against the recombinant SagA [23]
aLysM Rabbit serum raised against the recombinant LysM This study
aPpiC Rabbit serum raised against the recombinant PpiC This study
aDdcP Rabbit serum raised against the recombinant DdcP This study
aPBP5 Rabbit serum raised against the recombinant PBP5 This study
*ARE, ampicillin resistant enterococci; CC17, clonal linage complex 17; DdcP, D-alanyl-D-alanine carboxypeptidase; PBP5, low affinity penicillin-binding protein 5; PpiC,
peptidyl-prolyl cis-trans isomerase; SagA; major secreted antigen; VRE, vancomycin resistant enterococci.
doi:10.1371/journal.pone.0111880.t001
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2.3.02 program (Matrix Science). A database corresponding to an
updated compilation download from the NCBI database was used
with E. faecium as selected species (including 169 998 entries). The
variable modifications allowed were as follows: C-Carbamido-
methyl, K-acetylation, methionine oxidation, and dioxidation.
Trypsin was selected as the enzyme, with three miss cleavages also
allowed. Mass accuracy was set to 200 p.p.m. and 0.6 Da for MS
and MS/MS modes, respectively. Finally, to confirm the identity
of the recombinant proteins after affinity purification, SDS-PAGE
and Coomassie blue staining, the protein-containing regions
(bands) were excised, and washed twice with ultrapure water
and once with acetonitrile/50 mM ammonium bicarbonate (1:1,
v/v). Samples were stirred for 15 min and vacuum-dried for
30 min. In-gel digestion of the excised protein bands was carried
out using 0.5 mg trypsin, incubating overnight at 37uC. MS
analysis was performed as described above.
Determination of protein subcellular localization
The subcellular localization of the proteins was determined
using two different in silico approaches as follows. The sequence of
the identified proteins given by the MS analyses were retrieved
from the NCBI data base and analyzed with two Web-server




PCR was performed with Phusion highfidelity DNApolymerase
(Finnzymes). The primers used are listed in Table 2. PCR
products and plasmids were purified using the NucleoSpin plasmid
kit (Macherey-Nagel). Restriction enzymes and T4 DNA ligase
were purchased from Promega and used as recommended by the
manufacturer. Genomic DNA extraction and other standard
techniques were carried out as described by Sambrook et al. [43].
Construction of E. coli strains M15/pQE30LysM, M15/
pQE30PpiC, M15/pQE30PBP5 and M15/pQE30DdcP
The proteins were recombinantly expressed to raise antibodies
against the different antigens. The respective genes were amplified
without the signal peptide using primers listed in Table 2 and
genomic DNA from the E. faecium E155 as template. The
amplified genes were then inserted downstream of the IPTG
(Isopropyl b-D-1-thiogalactopyranoside)-inducible promoter into
the pQE30 expression vector (QIAexpressionist kit; Qiagen) to
obtain an N-terminal His6-tagged recombinant protein. The
resulting construct was electroporated into the E. coli M15pREP4,
creating the different M15/pQE30protein strains (see Table 1).
Recombinant proteins were overproduced and purified under
denaturing conditions using the Protino Ni-NTA Agarose
(Macherey-Nagel) resin, following the manufacture instructions.
Finally, the purified recombinant proteins were desalted by
diafiltration using the Amicon Ultra-15 Centrifugal Filter Units
of 3 KDa (Merck-Millipore).
Opsonophagocytic assay (OPA) and opsonophagocytic
inhibition assay (OPIA)
An in vitro opsonophagocytic assay (OPA) was performed as
described elsewhere [23,44]. Briefly, four components were
prepared: (a) baby rabbit serum (Cedarlane Laboratories)
absorbed with the target bacterial strain as a source of
complement, (b) the different rabbit sera (see table 1), (c)
polymorphonuclear neutrophils (PMNs) freshly prepared from
human blood collected from healthy adult volunteers, and (d) the
bacterial strains grown to OD650 nm = 0.4 in tryptic soy Broth
(TSB). For the assay, the four components were mixed: 100 mL of
PMNs (2.56104 mL21); 100 mL of the appropriate serum dilution,
100 mL of complement (1:30 dilution for E. faecium strains and
1:15 for E. faecalis strains), and 100 mL of an appropriate dilution
of bacteria to yield the desired colony counts (i.e. 1:1 relation
PMNs/bacteria). The mixture was incubated on a rotor rack at
37uC for 90 min, and samples were plated on TSA plates in
quadruplicate at time 0 and after 90 min. Percent killing was
calculated by comparing the colony counts of a control without
PMN’s to the colony counts after a 90-minute incubation at 37uC
(T90). For inhibition studies, rabbit serum was diluted 1:50 and
incubated for 60 min at 4uC with an equal volume of a diluted
sera containing 100 mg of the corresponding protein. Subsequent-
ly, the absorbed-serum was used in the OPA as described above.
Inhibition assays were performed at serum dilutions yielding 50–
60% killing of the inoculum without the addition of the inhibitor.
The percentage of inhibition of opsonophagocytic killing was
compared to controls without inhibitor.
Animal model
A mouse bacteremia model was performed to evaluate the
passive protection conferred by antibodies raised against the
recombinant proteins as described elsewhere [45,46] with some
modifications. In brief, Five female Balb-C mice 6 to 8 weeks-old
(Charles River) received intravenously 200 mL of NRS, serum
raised against the recombinant proteins or serum raised against
Table 2. Primers used in this study.
Primer name 59-39sequence+ Restriction site
LysM-5-BamHI-2 aggcGGATCCGATGAAGTTTATACAGTAAAATC BamH I
LysM-3-PstI aggcCTGCAGGGCTTAGTACCAGCCGTTTG Pst I
DdcP-5-BamHI-2 aggcGGATCCGAAGATACTTTCAAAGTAAATG BamH I
DdcP -3-PstI aggcCTGCAGCAATTAAAACAAGTTACCGAAAA Pst I
PpiC-5-BamHI-2 aggcGGATCCTGTTCAGGCGATACTAATAAAG BamH I
PpiC-3-SacI aggcGAGCTCCTTTTATTTTGATGAATCAGTTG Sac I
PBP5-5-BamHI aggcGGATCCATGAAAAGAAGTGACAAGCACG BamH I
PBP5-3-SacI aggcGAGCTCAGCAATTTTTTATTGATAATTTTGGS Sac I
+Bases in lowercase letters are not complementary to the target sequence.
Underlined bases correspond to restriction sites.
doi:10.1371/journal.pone.0111880.t002
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recombinant protein SagA as a positive control, 48 and 24 h
before the challenge. Bacterial inoculum of E. faecium E155
(5.26108 c.f.u per mouse) was injected via the tail vein (i.v.). 24 h
after challenge, mice were sacrificed and colony counts in kidneys
were determined by homogenizing and plating of serial dilutions.
Statistical Analysis
The software program GraphPad PRISM version 5.00 was used
for the statistical analyses. The percentage of organisms killed
using immune sera in the OPA was expressed as geometrical mean
6 the standard error of the means. Statistical significance for the
OPA and OPIA was determined by ANOVA and Dunnett’s
Multiple Comparison Test. A p value of ,0.05 was considered
significant. Significance of the bacterial counts in the animal
experiment was determined by analysis of variance for multi-group
comparisons using log-transformed data, and Dunnett post hoc
test. A p value of ,0.05 was considered significant.
Ethics Statement
All animal experiments were performed in compliance with the
German animal protection law (TierSchG). The mice were housed
and handled in accordance with good animal practice as defined
by FELASA and the national animal welfare body GV-SOLAS.
The animal welfare committees of the University of Freiburg
(Regierungspraesidium Freiburg Az 35/9185.81/G-12/070) ap-
proved all animal experiments.
Results
Identification of surface related proteins in E. faecium
E155
For a more accurate identification of surface proteins in the E.
faecium E155 strain, three different approaches were used: trypsin
shaving, biotinylation and high pH elution. The number of
proteins identified by MS analysis containing at least one unique
peptide in at least two sample replicates (see supplementary tables
S1 to S3) for the different methods were 390 for trypsin shaving,
309 for elution at high pH, and 45 for biotinylation. We analyzed
the sequence of each protein through two Web-server predictors
(CELLO v.2.5 and Gpos-mPLoc) to evaluate their sub-cellular
localization. For each of the three methods, proteins were then
classified in three main groups: a) Inside: If a protein was predicted
to have an exclusively cytoplasmic location by both algorithms we
considered it to be inside of the cell. b) Both: If one of the
algorithms predicted that the subcellular localization of a protein is
intracellular (cytoplasmic) and the other predicted that is outside of
the cytoplasm (i.e. membrane, cell wall associated and/or
extracellular) OR if the algorithms predicts two locations inside
Figure 1. Distribution of E. faecium E155 proteins identified by the different extraction methods. (A) Rate of E. faecium E155 proteins
identified with one or more unique peptides in at least two biological replicates by trypsin shaving, elution at high pH and biotinylation and their
corresponding subcellular localization predicted by Cellov.2.5 (http://cello.life.nctu.edu.tw) and Gpos-mPLoc (http://www.csbio.sjtu.edu.cn/bioinf/
Gpos-multi). (B) Venn-diagram of all the proteins identified by the different extraction methods. (B1) Correlation between the proteins extracted by
the different extraction methods. (B2) Correlation between the proteins predicted to have both cytoplasmic and extracytoplasmic location by CELLO
v.2.5 and Gpos-mPLoc. (B3) Correlation between the Proteins predicted to have exclusively an extracytoplasmic location by CELLO v.2.5 and Gpos-
mPLoc.
doi:10.1371/journal.pone.0111880.g001
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and outside of the cytoplasm (Cytoplasm-membrane or cytoplasm-
extracellular) at the same time, the protein was considered to be
both inside and outside of the cytoplasm. c) Surface-associated: If a
protein was predicted to have an exclusively extracytoplasmic
location (i.e. membrane, cell wall associated and/or extracellular)
by both algorithms we considered these proteins as surface-
associated. Among all the proteins identified, 39 (10%), 47 (15%)
and 27 (63%) polypeptides were predicted to be extracytoplasmic
by trypsin shaving, elution at high pH, and biotinylation,
respectively (see figure 1A). On the other hand, we observed that
102 (26%) proteins obtained by trypsin shaving, 85 (27%) by
elution at high pH and 4 (9%) by biotinylation were predicted to
have both cytoplasmic and extracytoplasmic location. The data
were then compared using Venn-diagrams (figure 1B1) to identify
proteins classified as surface-associated by more than one method.
A total of 552 proteins with at least one unique peptide were
uncovered and among them 16 proteins were identified by all
three methods; 158 proteins appeared at least in two of the three
different extraction procedures. We compared the proteins
predicted to have cytoplasmic and extracytoplasmic localizations
(see figure 1B2). Three of them were part of those polypeptides
identified by all three methods, while 36 appeared at least in two
(see supplementary table S4). Finally, we compared the proteins
that were predicted to have an extracytoplasmic location
(figure 1B3), showing that six of them appeared in all the
extraction methods and 23 were identified by at least two of the
three methods. Extracytoplasmic proteins identified by more than
one method and their subcellular localization are summarized in
table 3. Considering these results, we assumed that the six
extracytoplasmic proteins identified by all three extraction
methods were the most promising candidates to study immuno-
genicity and protective efficacy. Among the six proteins, we finally
Table 3. Summary of the proteins identified by at least two of the three extraction methods and predicted to have an
extracytoplasmic location.
Subcellular localizationb Extraction method
Protein name Gene Locusa CELLO v.2.5 Gpos-mPLoc Biot* Tryp1 HpH$
Peptidoglycan-binding protein LysM EFF34034 Ext-CW Ext-Cw + + +
Low affinity penicillin-binding protein 5 EFF35784 Ext Ext-CW + + +
D-alanyl-D-alanine carboxypeptidase EFF35669 Mem Mem + + +
PpiC-type peptidyl-prolyl cis-trans isomerase EFF34785 Ext-Mem Ext-Mem + + +
SCP-like extracellular protein EFF35540 Ext Ext + + +
Basic Membrane lipoprotein EFF34523 Ext Mem + + +
Glycosyl transferase EEV52587 Ext Ext + + 2
DNA-entry nuclease EEI59681 Ext Ext + 2 +
Extracellular solute-binding protein, family 5 EAN09846 Ext Ext + 2 +
NLPA lipoprotein EAN09985 Mem Mem + 2 +
Peptidase M41, FtsH EAN10268 Mem Mem + 2 +
Extracellular solute-binding protein, family 3 EAN08986 Mem Mem + 2 +
Periplasmic solute binding protein EAN10630 Mem Mem + 2 +
Cell envelope-related transcriptional
attenuator
EAN08970 Ext Ext 2 + +
Peptidase S1, chymotrypsin EAN09870 Ext-Mem Ext 2 + +
Beta-ketoacyl-acyl carrier protein
synthase III (FabH)
EAN10058 Mem Ext 2 + +
50S ribosomal protein L2 EEI61156 Mem Ext 2 + +
Peptidylprolyl isomerase EEI59596 Mem Ext 2 + +
Metallo-beta-lactamase superfamily protein EEV42569 Mem Ext 2 + +
Penicillin-binding protein EEV43240 Ext Mem 2 + +
ABC superfamily ATP binding cassette
transporter
EEI61138 Mem Mem 2 + +
Family 2 glycosyltransferase EEI61366 Mem Mem 2 + +
VANA ligase CAA40215 Mem Mem 2 + +
PilT protein, N-terminal EAN10184 Mem Mem 2 + +
Helicase, C-terminal: DEAD/DEAH
box helicase
EAN08953 Mem Mem 2 + +
aGene locus given by blast in the NCBI (http://www.ncbi.nlm.nih.gov/);
bsubcellular localization predicted by Cellov.2.5 (http://cello.life.nctu.edu.tw) and Gpos-mPLoc (http://www.csbio.sjtu.edu.cn/bioinf/Gpos-multi).
CW, cell wall. Ext, extracellular. Mem, membrane.
*Biot; Biotinylation.
1Tryp; Trypsin shaving.
$HpH; Elution at high pH.
doi:10.1371/journal.pone.0111880.t003
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decided to focus on four that interact with peptidoglycan (PG) and
are more likely to be surface-exposed: (a) the 21.6 kDa peptido-
glycan-binding protein LysM (LysM) that has been reported to be
non-covalently attached to PG [47]; (b) the 73.7 kDa low-affinity
penicillin-binding protein 5 (PBP5) that is involved in polymeri-
zation of PG [48–50], (c) the 47.7 kDa D-alanyl-D-alanine
carboxypeptidase (DdcP) - a low molecular weight penicillin
binding protein (LMW-PBP) cross-linking PG chains to form rigid
cell walls [49,51] and (d) the 37.3 kDa PpiC-type peptidyl-prolyl
cis-trans isomerase (PpiC) also involved in PG cross-linking [52].
The target proteins induce opsonic and cross-reactive
antibodies
The genes encoding the four candidate proteins were amplified
without their signal peptides, cloned into the pQE30 expression
vector and transformed into E. coli. The recombinant proteins
were then purified under denaturing conditions. The purity of the
proteins was assessed by SDS-PAGE and their identity was
confirmed by LC-MS/MS (data not shown). New Zeeland white
rabbits were immunized with purified proteins and exsanguinated
two weeks after the last injection. The obtained polyclonal
antibodies raised against the different proteins were tested in an
OPA against the corresponding strain E. faecium E155 showing
that all the proteins were able to induce opsonic antibodies.
Different concentrations were tested to titer out the opsonic
activity of the sera. Maximum opsonic activity of the antibodies
was between 58–65% of killing with a 1:10 serum dilution, and a
reduction of killing was observed in a dose dependent fashion
using increasingly higher dilutions of sera (see figure 2). To verify
the specificity of the killing against the respective recombinant
protein, opsonophagocytic inhibition assays (OPIA) were
carried out by pre-incubating the sera with 100 mg/mL of the
Figure 2. Opsonophagocytic assay against the homologous strain E. faecium E155. Opsonophagocytic assay used to test the ability to
mediate opsonic killing in the strain E. faecium E155 by antibodies raised against the recombinant proteins at different dilutions. aPpiC (square grid),
aPBP5 (horizontal stripes), aLysM (vertical stripes) and aDdcP (rhombic grid), compare with the activity of the preimune rabbit serum (NRS, white bar).
Bars represent the mean of data and the error bars represent the standard error of the mean. Statistical significance was determined by ANOVA and
Dunnett’s Multiple Comparison Test. Comparing killing rates of similar dilutions (i.e. 1:10) with the NRS, all comparisons were significant at p,0.001
(indicated by asterisk).
doi:10.1371/journal.pone.0111880.g002
Figure 3. Specificity of the antibodies raised against the recombinant proteins. The sera were used at final dilution of 1:50, PpiC (square
grid), PBP5 (horizontal stripes), LysM (vertical stripes) and DdcP (rhombic grid) and the strain tested was E. faecium E155. Purified recombinant
proteins were used as inhibitors at concentration of 100 mg/mL, and were preincubated with the corresponding sera dilution for 1 h at 4uC prior to
OPA. Opsonic killing of the target strain with non-absorbed antibodies was used to assess the reduction of opsonic killing produced by each inhibitor,
using preimune rabbit serum (NRS, white bar) as a Control. Bars represent the mean of data and the error bars represent the standard error of the
mean. Statistical significance was determined by ANOVA and Dunnett’s Multiple Comparison Test. Comparing killing rates of similar dilutions (i.e.
1:50) with the NRS, all comparisons were significant at p,0.001 (indicated by asterisk).
doi:10.1371/journal.pone.0111880.g003
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corresponding recombinant protein. These sera were then tested
in an OPA using E. faecium strain E155 which showed that
opsonic killing is inhibited by more than 85% in all cases (see
figure 3).
Specific and opsonic antibodies against the recombinant
proteins are cross-reactive with different E. faecium and
E. faecalis isolates
To determine if the antibodies directed against the recombinant
proteins were able to opsonize different strains, serum dilutions
between 1:10 and 1:100 were tested in OPAs against E. faecium
E1162 and E. faecalis 12030, type 2 and type 5 [46,53]. The four
sera were able to opsonize all strains exhibiting killing above 60%
(see Figure 4A and 4B). Passive immunization with antibodies
directed against the different proteins promotes clearance of
bacteria in mice
To determine if antibodies directed against the recombinant
proteins are protective in a mouse bacteremia model, mice were
passively immunized twice within 48 h before bacterial infection.
Sera raised against the four recombinant proteins significantly
reduced E. faecium E155 colony counts in the kidneys. These
results are comparable to the protection achieved by antibodies
raised against the previously reported antigen SagA [23].
Immunization with the sera raised against PpiC and PBP5
Figure 4. Cross-reactivity of the sera against different enterococcal strains. Opsonophagocytic assay used to test the ability to mediate
opsonic killing of different enterococcal strains by antibodies raised against the recombinant proteins. A) Opsonophagocytic killing of strains E.
faecium E1162 and E. faecalis 12030 by antibodies raised against the recombinant proteins at dilutions between 1:10 and 1:100. aPpiC (square grid),
aPBP5 (horizontal stripes), aLysM (vertical stripes) and aDdcP (rhombic grid), compared with the activity of the preimune rabbit serum (NRS, white
bar). B) Opsonophagocytic killing in E. faecalis type 2 and E. faecalis type 5 by antibodies raised against the recombinant proteins at dilution 1:10.
aPpiC (square grid), aPBP5 (horizontal stripes), aLysM (vertical stripes) and aDdcP (rhombic grid), compared with the activity of the preimune rabbit
serum (NRS, white bar). Bars represent the mean of data and the error bars represent the standard error of the mean. Statistical significance was
determined by ANOVA and Dunnett’s Multiple Comparison Test. Comparing killing rates of similar dilutions (i.e. 1:10, 1:50 or 1:100) with the NRS, all
comparisons were significant at p,0.001 (indicated by asterisk).
doi:10.1371/journal.pone.0111880.g004
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proteins resulted in higher viable counts (i.e. less protection) (P
value#0.05) compared to serum raised against DdcP (P value#
0.01) and LysM (P value#0.001) (see Figure 5).
Discussion
It has been reported by in silico analysis that between 30 to 40%
of the bacterial proteome corresponds to surface-associated
proteins. However, few of these proteins have been physicochem-
ically and immunologically characterized [26], although surface-
exposed and secreted proteins have been shown to be promising
vaccine candidates in some pathogenic bacterial species
[23,54,55]. Surface-exposed proteins can be identified more or
less successfully by in silico approaches or with different extraction
methods, such as trypsin shaving and biotinylation
[15,26,27,36,54]. Maione et al. used multiple genome screening
approaches in group B Streptococcus, identifying 589 predicted
surface-exposed proteins. They overexpressed and tested 312 of
these candidates, but only four were found to be potential vaccine
candidates [54]. In group A Streptococcus, trypsin shaving has
been shown to be a useful technique to extract surface-exposed
proteins. Rodrı́guez-Ortega and coworkers were able to identify
72 proteins and demonstrate that 95% corresponded to extra-
cytoplasmic proteins and around 86% of them were effectively
surface-exposed [26]. However, in our study trypsin shaving was
not the most efficient method. Indeed, only 36% of the identified
proteins were predicted to have an extracytoplasmic location. This
is in agreement with the findings of Hempel et al. in Staphylo-
coccus aureus, showing that by trypsin shaving only 41% of the
extracted proteins corresponded to surface-exposed proteins [27].
It is important to point out that some of these proteins that we
classified as cytoplasmic proteins by different web-server predictors
(e.g. enolase, Inosine-59-monophosphate dehydrogenase, glyceral-
dehyde-3-phosphate dehydrogenase, pyruvate dehydrogenase,
triosephosphate isomerase, elongation factor Tu, and GroEL)
have been described as ‘‘moonlight proteins’’ since they perform
more than one function on the cell [56,57] and have been
identified on the cell surface of some gram-positive bacterial
pathogens [33,58–67]. Although the proteins mentioned above are
predicted to be cytoplasmic we cannot be ruled out their possible
surface location and should be consider as good candidates for
further immunological studies. The combined results may indicate
that the efficiency of trypsin shaving may be species-dependent. In
the case of E. faecium, we demonstrated that biotinylation was the
most accurate and specific procedure for the identification of
extracytoplasmic proteins with a yield of 72%. In the present study
the killing of bacteria in the opsonophagocytic assay indicates that
the respective target is accessible for antibodies and complement.
However, additional methods (such as immuno-electron micros-
copy or confocal microscopy) are necessary to confirm surface
exposure.
Only one protein has been identified so far as a potential
vaccine target in E. faecium. The major secreted protein SagA
induced opsonic and protective antibodies in rabbit, that were able
to mediate in vitro opsonophagocytic killing against the homol-
ogous strain and to reduce colony counts in mice [23].
Additionally, an antibody isolated from a phage display antibody
library, directed against an epitope present in an ABC transporter
protein has been described to promote clearance of E. faecium in
mice, suggesting its possible use in immunotherapy [24]. The
peptidoglycan-associated proteins tested as vaccine candidates in
the present study have been implicated in antibiotic resistance and
virulence. Penicillin-binding proteins, such as PBP5 and Ddcp,
have been reported to play a key role in intrinsic resistance to b-
lactams, being the major contributors to ampicillin resistance in E.
faecium [51]. In E. faecalis, the homologue to protein PpiC has
been characterized as a potential virulence factor that confers
resistance to high NaCl concentrations and ampicillin, because
this protein is involved in the folding and trafficking of
extracellular proteins, especially PBPs [52,68]. LysM, which is
non-covalently attached to peptidoglycan, has been reported to be
involved in early stages of erythromycin resistance in E. faecalis,
but its precise function has not been elucidated yet [69]. All these
proteins are clearly potential targets for drug development and we
show here that they could also be interesting for vaccine
development.
We were able to demonstrate that all four proteins induced
opsonic antibodies in rabbits, which mediate effectively in vitro
opsonophagocytic killing (higher than 50%) not only of the
homologous strain but also of other enterococcal strains, i.e. E.
faecium E1162 (belonging to clonal complex 17 [70]), E. faecalis
12030, E. faecalis type 2 and E. faecalis type 5 [53]. The broad
cross-reactivity of the sera indicates that these protein antigens
may effectively supplement serotype-dependent coverage of
polysaccharide-based vaccines. The lower opsonophagocytic
killing observed against the homologous strain compared with E.
Figure 5. Protection against bacteremia in mice. Passive
Immunization with the antibodies raised against the recombinant
proteins promotes clearance of E. faecium E155 in mouse kidney in
comparison with the normal rabbit serum. 24 h after the bacterial
challenge mice were killed and kidneys were removed to assess viable
counts. Each point represents the bacterial counts from a single mouse.
Bars indicate the median CFU/100 mg of kidney for the group. P value
was ,0.05 (*P#0.05, **P#0.01, ***P#0.001) for comparison between
the animals immunized with the antibodies raised against the
recombinant proteins and control animals immunized with preimune
rabbit serum (NRS) determined by analysis of variance for multi-group
comparisons using on log-transformed data, and Dunnett post hoc test.
doi:10.1371/journal.pone.0111880.g005
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faecium E1162 and E. faecalis 12030, may be attributed to the
surface accessibility of the protein antigens that vary from strain to
strain, even if the antigen’s encoding genes are conserved [54].
Such variability may be due to differences in gene expression,
antigen masking by other cell wall components, protein degrada-
tion, or other factors [26,54]. The presence of a putative
antiphagocytic polysaccharide capsule in E. faecium E155, similar
to the one found in E. faecalis serotypes C and D, may mask
protein antigens, making them less available for binding or less
accessible for complement components or phagocytes [46]. A
similar effect was observed for E. faecalis Type 2 and Type 5 since
these strains were killed to a lesser extent than E. faecalis 12030.
Compared to this strain, 10 times higher serum concentrations
were necessary to observe similar killing of these strains,
strengthening the suggestion that masking may be the reason for
the reduced opsonophagocytic killing observed in E. faecium
E155. Specificity of the sera raised against the different proteins
was demonstrated by the reduction of the opsonophagocytic killing
elicited by serum absorbed with the corresponding recombinant
protein. The OPA is known to correlate well with in vivo immune
response and is considered a surrogate for the human protective
immune response [10]. This assay is an indicator for the bacteria’s
ability to survive in the human blood and to cause infections [71].
We observed a good correlation between the ability of the
antibodies raised against the different recombinant proteins to
mediate opsonic killing in vitro and promote a statistically
significant reduction of bacteria in mice after i.v. challenge.
In summary, we compared three existing extraction methods for
bacterial surface proteins that are likely to interact with the host
immune system. These proteins can be targets for drugs aimed at
preventing bacterial infections and diseases, or could be used as
components for conjugate vaccines. We demonstrate that the four
peptidoglycan associated proteins identified by this approach, i.e.
LysM, DdcP, PpiC and PBP5 elicit specific, opsonic and protective
antibodies, with a broad cross-reactivity and serotype-independent
coverage among E. faecalis and E. faecium. These antigens are
interesting targets to be used as single component or as carrier
proteins together with polysaccharide antigens in vaccine devel-
opment against enterococcal infections.
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Ortega MJ (2013) Identification of potential new protein vaccine candidates
through pan-surfomic analysis of pneumococcal clinical isolates from adults.
PLoS One 8: e70365. doi:10.1371/journal.pone.0070365.
19. Assaad U, El-Masri I, Porhomayon J, El-Solh AA (2012) Pneumonia
immunization in older adults: review of vaccine effectiveness and strategies.
Clin Interv Aging 7: 453–461. doi:10.2147/CIA.S29675.
20. Mond JJ, Lees A, Snapper CM (1995) T cell-independent antigens type 2. Annu
Rev Immunol 13: 655–692. doi:10.1146/annurev.iy.13.040195.003255.
21. Singh K V, Nallapareddy SR, Sillanpää J, Murray BE (2010) Importance of the
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